SCHEMBL4833432

SCHEMBL4833432

CC(=O)NC1(c2ccccc2)CCN(CCC2c3ccccc3CCN2C(=O)CC(C)CC(C)(C)C)CC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 1/20 0.40
POLB P06746 1/20 0.39
TACR2 P21452 2/20 0.37
TACR1 P25103 2/20 0.37
OPRD1 P41143 3/20 0.37
ALDH1A1 P00352 3/20 0.36
CYP2C19 P33261 1/20 0.36
HHAT Q5VTY9 3/20 0.36
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2D6 P10635 1/20 0.35
TACR3 P29371 1/20 0.35
DRD2 P14416 1/20 0.35
ACE P12821 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839028 0.88 POLB (0.43) MTNR1BPOLBTACR2TACR1OPRD1
SCHEMBL4837245 0.80 ALDH1A1 (0.50) MTNR1BPOLBALDH1A1CYP2C19TACR3
SCHEMBL4837378 0.79 ALDH1A1 (0.52) MTNR1BPOLBALDH1A1CYP2C19TACR3
SCHEMBL4833126 0.79 ALDH1A1 (0.52) MTNR1BPOLBALDH1A1CYP2C19TACR3
SCHEMBL4839655 0.79 OPRM1 (0.46) MTNR1BPOLBTACR2TACR1ALDH1A1
SCHEMBL4838204 0.79 POLB (0.42) MTNR1BPOLBTACR2TACR1ALDH1A1
SCHEMBL4837665 0.79 DRD3 (0.43) MTNR1BPOLBTACR2TACR1ALDH1A1
SCHEMBL4830126 0.79 TACR3 (0.45) POLBTACR3DRD2
SCHEMBL4836727 0.79 POLB (0.42) MTNR1BPOLBTACR2TACR1OPRD1
SCHEMBL4835945 0.78 MTNR1B (0.40) MTNR1BOPRD1HHATCYP2D6DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 MTNR1B 621/4885POLB 4382/4885TACR2 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.